BG61370B2 - Заместени андроста-1,4-диен-3,17-диони и метод за тяхното получаване - Google Patents

Заместени андроста-1,4-диен-3,17-диони и метод за тяхното получаване Download PDF

Info

Publication number: BG61370B2
Authority: BG; Bulgaria
Prior art keywords: dione; compound; diene; formula; hydrogen
Prior art date: 1985-07-09

Application number

BG098516A

Other languages

Bulgarian (bg)

English (en)

Inventor

Franco Buzzetti

Natale Barbuglan

Paolo Lombardi

Enrico Di-Salle

Original Assignee

Pharmacia Italia S.P.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-07-09

Filing date

1994-02-22

Publication date

1997-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10582036&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG61370(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-02-22 Application filed by Pharmacia Italia S.P.A. filed Critical Pharmacia Italia S.P.A.

1997-06-30 Publication of BG61370B2 publication Critical patent/BG61370B2/bg

Links

238000000034 method Methods 0.000 title claims abstract description 26
238000002360 preparation method Methods 0.000 title claims abstract description 6
150000001875 compounds Chemical class 0.000 claims abstract description 92
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 29
239000001257 hydrogen Substances 0.000 claims abstract description 27
150000002431 hydrogen Chemical group 0.000 claims abstract description 11
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 9
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 9
230000001419 dependent effect Effects 0.000 claims abstract description 8
229910052736 halogen Inorganic materials 0.000 claims abstract description 5
150000002367 halogens Chemical group 0.000 claims abstract description 5
OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims description 55
239000000203 mixture Substances 0.000 claims description 21
239000000460 chlorine Substances 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 8
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 7
239000003153 chemical reaction reagent Substances 0.000 claims description 7
229910052731 fluorine Inorganic materials 0.000 claims description 7
239000011737 fluorine Substances 0.000 claims description 7
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
229910052801 chlorine Inorganic materials 0.000 claims description 6
206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 5
208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 5
238000006356 dehydrogenation reaction Methods 0.000 claims description 5
229940088597 hormone Drugs 0.000 claims description 5
239000005556 hormone Substances 0.000 claims description 5
MRPVKCAISORZMV-TYFMXVJSSA-N (8r,9s,10r,13s,14s)-6-ethylidene-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound C([C@@]12C)=CC(=O)C=C1C(=CC)C[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@H]21 MRPVKCAISORZMV-TYFMXVJSSA-N 0.000 claims description 4
206010006187 Breast cancer Diseases 0.000 claims description 4
208000026310 Breast neoplasm Diseases 0.000 claims description 4
206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
FLZJERIREHTZGS-DZFIUHNSSA-N (8r,9s,10s,13s,14s)-4-chloro-1,10,13-trimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C(Cl)=C3C(=C)C[C@H]2[C@@H]2CCC(=O)[C@]21C FLZJERIREHTZGS-DZFIUHNSSA-N 0.000 claims description 3
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims description 3
210000000481 breast Anatomy 0.000 claims description 3
230000002357 endometrial effect Effects 0.000 claims description 3
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims description 3
UGMALTYFJCIPHD-RDVHEEPHSA-N (8r,9s,10r,13s,14s)-4-chloro-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1Cl UGMALTYFJCIPHD-RDVHEEPHSA-N 0.000 claims description 2
FSHBBMIQSIBZQD-RDVHEEPHSA-N (8r,9s,10r,13s,14s)-4-fluoro-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1F FSHBBMIQSIBZQD-RDVHEEPHSA-N 0.000 claims description 2
NZSZWFHPDWZPMV-YRJWVXGYSA-N (8r,9s,10s,13s,14s)-1,10,13-trimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3C(=C)C[C@H]2[C@@H]2CCC(=O)[C@]21C NZSZWFHPDWZPMV-YRJWVXGYSA-N 0.000 claims description 2
MSWDXKNJTDCILH-FHHGAAIESA-N (8r,9s,10s,13s,14s)-1-ethyl-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound C1C[C@@H]2[C@@]3(C)C(CC)=CC(=O)C=C3C(=C)C[C@H]2[C@@H]2CCC(=O)[C@]21C MSWDXKNJTDCILH-FHHGAAIESA-N 0.000 claims description 2
206010014733 Endometrial cancer Diseases 0.000 claims description 2
206010033128 Ovarian cancer Diseases 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
201000004240 prostatic hypertrophy Diseases 0.000 claims 2
BVCKDXQMHVMAQI-KUVPCWQVSA-N (8r,9s,10r,13s,14s)-4,10,13-trimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound C([C@]1(C)C(=O)CC[C@H]1[C@@H]1CC2=C)C[C@@H]1[C@]1(C)C2=C(C)C(=O)C=C1 BVCKDXQMHVMAQI-KUVPCWQVSA-N 0.000 claims 1
WLWSBPBOCMIGEJ-IDRUFVAWSA-N (8r,9s,10r,13s,14s)-4-ethyl-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound C([C@]1(C)C(=O)CC[C@H]1[C@@H]1CC2=C)C[C@@H]1[C@]1(C)C2=C(CC)C(=O)C=C1 WLWSBPBOCMIGEJ-IDRUFVAWSA-N 0.000 claims 1
PXWUIYKFPZVOJH-DZFIUHNSSA-N (8r,9s,10r,13s,14s)-6-ethylidene-4-fluoro-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound C([C@@]12C)=CC(=O)C(F)=C1C(=CC)C[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@H]21 PXWUIYKFPZVOJH-DZFIUHNSSA-N 0.000 claims 1
XEOFRLMFLCBVOC-DZFIUHNSSA-N (8r,9s,10s,13s,14s)-4-fluoro-1,10,13-trimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C(F)=C3C(=C)C[C@H]2[C@@H]2CCC(=O)[C@]21C XEOFRLMFLCBVOC-DZFIUHNSSA-N 0.000 claims 1
XXQPWIJQPXWLLJ-FHHGAAIESA-N (8r,9s,10s,13s,14s)-6-ethylidene-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound CC([C@@]12C)=CC(=O)C=C1C(=CC)C[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@H]21 XXQPWIJQPXWLLJ-FHHGAAIESA-N 0.000 claims 1
239000004480 active ingredient Substances 0.000 claims 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
201000002528 pancreatic cancer Diseases 0.000 claims 1
208000008443 pancreatic carcinoma Diseases 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 abstract description 7
201000011510 cancer Diseases 0.000 abstract description 5
239000013543 active substance Substances 0.000 abstract description 3
241000124008 Mammalia Species 0.000 abstract 1
230000000144 pharmacologic effect Effects 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 33
239000000243 solution Substances 0.000 description 29
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
-1 1,2-Propadienyl Chemical group 0.000 description 16
102000014654 Aromatase Human genes 0.000 description 14
108010078554 Aromatase Proteins 0.000 description 14
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
238000006243 chemical reaction Methods 0.000 description 12
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 11
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 9
229940011871 estrogen Drugs 0.000 description 9
239000000262 estrogen Substances 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
238000010992 reflux Methods 0.000 description 9
HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 8
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
238000000338 in vitro Methods 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
239000000741 silica gel Substances 0.000 description 8
229910002027 silica gel Inorganic materials 0.000 description 8
AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 7
239000002904 solvent Substances 0.000 description 7
239000000725 suspension Substances 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000012044 organic layer Substances 0.000 description 6
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 6
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
229960000583 acetic acid Drugs 0.000 description 5
239000003886 aromatase inhibitor Substances 0.000 description 5
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
229910052794 bromium Inorganic materials 0.000 description 5
239000002775 capsule Substances 0.000 description 5
238000011534 incubation Methods 0.000 description 5
239000012442 inert solvent Substances 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
LUJVUUWNAPIQQI-UHFFFAOYSA-N (+)-androsta-1,4-diene-3,17-dione Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 LUJVUUWNAPIQQI-UHFFFAOYSA-N 0.000 description 4
KQRGETZTRARSMA-DAELLWKTSA-N (8r,9s,10r,13s,14s)-10,13-dimethyl-6-methylidene-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 KQRGETZTRARSMA-DAELLWKTSA-N 0.000 description 4
BTTWKVFKBPAFDK-UHFFFAOYSA-N (9beta,10alpha)-Androst-4-ene-3,17-dione Natural products OC1CCC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 BTTWKVFKBPAFDK-UHFFFAOYSA-N 0.000 description 4
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 4
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
239000002253 acid Substances 0.000 description 4
LUJVUUWNAPIQQI-QAGGRKNESA-N androsta-1,4-diene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 LUJVUUWNAPIQQI-QAGGRKNESA-N 0.000 description 4
238000005899 aromatization reaction Methods 0.000 description 4
239000012043 crude product Substances 0.000 description 4
239000003480 eluent Substances 0.000 description 4
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 4
238000000926 separation method Methods 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000003826 tablet Substances 0.000 description 4
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 4
UYVYOWBHGWWYCL-OAGDOXAWSA-N (8S,9S,10R,13S,14S)-4,10,13-trimethyl-6-methylidene-3,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene Chemical compound CC1=C2C(C[C@H]3[C@@H]4CCC[C@@]4(C)CC[C@@H]3[C@]2(C=CC1)C)=C UYVYOWBHGWWYCL-OAGDOXAWSA-N 0.000 description 3
GUUBSBVZJBKPLY-YOWRRBNZSA-N (8S,9S,10R,13S,14S)-4-ethyl-10,13-dimethyl-6-methylidene-3,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene Chemical compound C(C)C1=C2C(C[C@H]3[C@@H]4CCC[C@@]4(C)CC[C@@H]3[C@]2(C=CC1)C)=C GUUBSBVZJBKPLY-YOWRRBNZSA-N 0.000 description 3
LLWYKSSAOMNDHF-BDCMKUQMSA-N (8r,9s,10r,13s,14s)-10,13-dimethyl-6-propylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound C([C@@]12C)=CC(=O)C=C1C(=CCC)C[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@H]21 LLWYKSSAOMNDHF-BDCMKUQMSA-N 0.000 description 3
YNBSLTCEHTXQPX-RAYVARHCSA-N 4,5-epoxy-6-methylenandrost-1-ene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C32OC31 YNBSLTCEHTXQPX-RAYVARHCSA-N 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
240000008042 Zea mays Species 0.000 description 3
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
235000002017 Zea mays subsp mays Nutrition 0.000 description 3
230000029936 alkylation Effects 0.000 description 3
238000005804 alkylation reaction Methods 0.000 description 3
239000003098 androgen Substances 0.000 description 3
229960005471 androstenedione Drugs 0.000 description 3
229940046844 aromatase inhibitors Drugs 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
238000009835 boiling Methods 0.000 description 3
235000005822 corn Nutrition 0.000 description 3
239000003814 drug Substances 0.000 description 3
229960000255 exemestane Drugs 0.000 description 3
239000010410 layer Substances 0.000 description 3
229910052744 lithium Inorganic materials 0.000 description 3
229910052749 magnesium Inorganic materials 0.000 description 3
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
229910052943 magnesium sulfate Inorganic materials 0.000 description 3
235000019341 magnesium sulphate Nutrition 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
235000010981 methylcellulose Nutrition 0.000 description 3
230000003228 microsomal effect Effects 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
239000001632 sodium acetate Substances 0.000 description 3
235000017281 sodium acetate Nutrition 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
229940032147 starch Drugs 0.000 description 3
150000003431 steroids Chemical group 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
ISMVMNHPEDSOTR-TXDMSJPOSA-N (8r,9s,10r,13s,14s)-4,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound C([C@]1(C)C(=O)CC[C@H]1[C@@H]1CC2)C[C@@H]1[C@]1(C)C2=C(C)C(=O)CC1 ISMVMNHPEDSOTR-TXDMSJPOSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
GIKNHHRFLCDOEU-UHFFFAOYSA-N 4-(2-aminopropyl)phenol Chemical compound CC(N)CC1=CC=C(O)C=C1 GIKNHHRFLCDOEU-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
101710162501 Ovarian aromatase Proteins 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
235000019270 ammonium chloride Nutrition 0.000 description 2
229940030486 androgens Drugs 0.000 description 2
DKVSUQWCZQBWCP-QAGGRKNESA-N androsta-1,4,6-triene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3C=CC2=C1 DKVSUQWCZQBWCP-QAGGRKNESA-N 0.000 description 2
WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
238000011161 development Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000012259 ether extract Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
230000003169 placental effect Effects 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000000829 suppository Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
150000003573 thiols Chemical class 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
BRVWJCVWAUQEGN-TZSWQHAOSA-N (1S,2S,11R,12S,16S)-9-ethylidene-2,3,16-trimethyl-7-oxapentacyclo[9.7.0.02,8.06,8.012,16]octadec-3-ene-5,15-dione Chemical compound CC([C@@]12C)=CC(=O)C3OC31C(=CC)C[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@H]21 BRVWJCVWAUQEGN-TZSWQHAOSA-N 0.000 description 1
RTNAGRUFWLBHEB-IDRUFVAWSA-N (8R,9S,10R,13S,14S)-6-ethylidene-4,10,13-trimethyl-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound C([C@@]12C)CC(=O)C(C)=C1C(=CC)C[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@H]21 RTNAGRUFWLBHEB-IDRUFVAWSA-N 0.000 description 1
NGONWFWOPQHNQH-KUVPCWQVSA-N (8r,9s,10r,13s,14s)-4,10,13-trimethyl-6-methylidene-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound C([C@]1(C)C(=O)CC[C@H]1[C@@H]1CC2=C)C[C@@H]1[C@]1(C)C2=C(C)C(=O)CC1 NGONWFWOPQHNQH-KUVPCWQVSA-N 0.000 description 1
YASLVRWGEDQYJN-TXTPUJOMSA-N (8r,9s,10s,13s,14s)-10,13-dimethyl-1-methylidene-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1CC(=C)[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 YASLVRWGEDQYJN-TXTPUJOMSA-N 0.000 description 1
SAJAXAOYSFGJRH-DZFIUHNSSA-N (8r,9s,10s,13s,14s)-4-bromo-1,10,13-trimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C(Br)=C3C(=C)C[C@H]2[C@@H]2CCC(=O)[C@]21C SAJAXAOYSFGJRH-DZFIUHNSSA-N 0.000 description 1
IWEIPZWVWLBKPK-VMXHOPILSA-N (8s,9s,10r,13s,14s)-10,13-dimethyl-2,3,8,9,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1=CC2=CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 IWEIPZWVWLBKPK-VMXHOPILSA-N 0.000 description 1
ORGMNSRXDIDLHH-JBDAPHQKSA-N (8s,9s,10r,13s,14s)-10,13-dimethyl-6-methylidene-3,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene Chemical compound C1C(=C)C2=CCC=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 ORGMNSRXDIDLHH-JBDAPHQKSA-N 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
WJIQCDPCDVWDDE-WZNAKSSCSA-N 5alpha-androst-1-ene-3,17-dione Chemical compound C1C(=O)C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 WJIQCDPCDVWDDE-WZNAKSSCSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
229940122815 Aromatase inhibitor Drugs 0.000 description 1
229910015900 BF3 Inorganic materials 0.000 description 1
IBAQPUZZTNVBMT-IEYYFSCXSA-N ClC1=C2C(C[C@H]3[C@@H]4CCC[C@@]4(C)CC[C@@H]3[C@]2(C=CC1)C)=C Chemical compound ClC1=C2C(C[C@H]3[C@@H]4CCC[C@@]4(C)CC[C@@H]3[C@]2(C=CC1)C)=C IBAQPUZZTNVBMT-IEYYFSCXSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
241000206672 Gelidium Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
244000043261 Hevea brasiliensis Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
239000004909 Moisturizer Substances 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
238000002679 ablation Methods 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
150000001348 alkyl chlorides Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000036983 biotransformation Effects 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000007859 condensation product Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000006477 desulfuration reaction Methods 0.000 description 1
230000023556 desulfurization Effects 0.000 description 1
SYZWSSNHPZXGML-UHFFFAOYSA-N dichloromethane;oxolane Chemical compound ClCCl.C1CCOC1 SYZWSSNHPZXGML-UHFFFAOYSA-N 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
238000006735 epoxidation reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
KLKFAASOGCDTDT-UHFFFAOYSA-N ethoxymethoxyethane Chemical compound CCOCOCC KLKFAASOGCDTDT-UHFFFAOYSA-N 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
230000010224 hepatic metabolism Effects 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
229940050176 methyl chloride Drugs 0.000 description 1
DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
210000001589 microsome Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000001333 moisturizer Effects 0.000 description 1
229920003052 natural elastomer Polymers 0.000 description 1
229920001194 natural rubber Polymers 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
KVNYFPKFSJIPBJ-UHFFFAOYSA-N ortho-diethylbenzene Natural products CCC1=CC=CC=C1CC KVNYFPKFSJIPBJ-UHFFFAOYSA-N 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
210000005059 placental tissue Anatomy 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000008057 potassium phosphate buffer Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
238000000746 purification Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
239000002594 sorbent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960005353 testolactone Drugs 0.000 description 1
BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BG098516A 1985-07-09 1994-02-22 Заместени андроста-1,4-диен-3,17-диони и метод за тяхното получаване BG61370B2 (bg)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB858517360A GB8517360D0 (en)	1985-07-09	1985-07-09	Substituted androsta-1,4-diene-3,17-diones

Publications (1)

Publication Number	Publication Date
BG61370B2 true BG61370B2 (bg)	1997-06-30

Family

ID=10582036

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG098516A BG61370B2 (bg)	1985-07-09	1994-02-22	Заместени андроста-1,4-диен-3,17-диони и метод за тяхното получаване

Country Status (38)

Country	Link
US (2)	US4808616A (it)
JP (1)	JPS6212797A (it)
KR (1)	KR950003614B1 (it)
CN (1)	CN86104664B (it)
AT (1)	AT395157B (it)
AU (1)	AU578840B2 (it)
BE (1)	BE905067A (it)
BG (1)	BG61370B2 (it)
BR (1)	BR1100240A (it)
CA (1)	CA1277656C (it)
CH (1)	CH668599A5 (it)
CS (2)	CS258498B2 (it)
CZ (1)	CZ413591A3 (it)
DE (1)	DE10199030I1 (it)
DK (1)	DK163520C (it)
ES (2)	ES8801304A1 (it)
FI (1)	FI83424C (it)
FR (1)	FR2584725B1 (it)
GB (2)	GB8517360D0 (it)
GR (1)	GR861780B (it)
HK (1)	HK94190A (it)
HU (1)	HU194274B (it)
IE (1)	IE58949B1 (it)
IL (1)	IL79336A (it)
IT (1)	IT1196436B (it)
MY (1)	MY102294A (it)
NL (2)	NL193616C (it)
NO (2)	NO165547C (it)
NZ (1)	NZ216763A (it)
PH (1)	PH21785A (it)
PT (1)	PT82944B (it)
SE (1)	SE468988B (it)
SG (1)	SG80490G (it)
SK (1)	SK413591A3 (it)
SU (2)	SU1442077A3 (it)
UA (1)	UA6046A1 (it)
YU (2)	YU44585B (it)
ZA (1)	ZA865079B (it)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8517360D0 (en) *	1985-07-09	1985-08-14	Erba Farmitalia	Substituted androsta-1,4-diene-3,17-diones
GB8617107D0 (en) *	1986-07-14	1986-08-20	Erba Farmitalia	6-/7-methylenandrosta-1 4-diene-3 17-dione derivatives
GB8622330D0 (en) *	1986-09-17	1986-10-22	Erba Farmitalia	4-substituted 6-alkylidenandrostene-3,17-dione derivatives
DE3715869A1 (de) *	1987-05-07	1988-11-17	Schering Ag	Verfahren zur herstellung von 1-methyl-androsta-1,4-dien-3,17-dion und die neuen zwischenprodukte fuer dieses verfahren
GB8721384D0 (en) *	1987-09-11	1987-10-21	Erba Farmitalia	17-substituted andro-sta-1 4-dien-3-one derivatives
GB8721383D0 (en) *	1987-09-11	1987-10-21	Erba Farmitalia	Preparation of methylene derivatives
GB8801697D0 (en) *	1988-01-26	1988-02-24	Erba Farmitalia	Improvements in synthesis of 6-methylene derivatives of androsta-1 4-diene-3 17-dione
ATE154032T1 (de) *	1991-03-28	1997-06-15	Teikoku Hormone Mfg Co Ltd	Neue d-homo-17-oxa und d-homo-17-aza- androstanderivate
CH683151A5 (de) *	1991-04-24	1994-01-31	Ciba Geigy Ag	Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus.
GB9201224D0 (en) *	1992-01-21	1992-03-11	Erba Carlo Spa	Difluoromethylenandrostenone derivatives and process for their preparation
ES2130284T3 (es) *	1992-09-30	1999-07-01	Teikoku Hormone Mfg Co Ltd	Compuesto de oxasteroides 7-sustituidos.
US6407082B1 (en) *	1996-09-13	2002-06-18	New Life Pharmaceuticals Inc.	Prevention of ovarian cancer by administration of a vitamin D compound
GB9313420D0 (en) *	1993-06-29	1993-08-11	Erba Carlo Spa	Fluorinated 6-methylenandrosta-1,4-dien-3-one-derivatives and process for their preparations
US6511970B1 (en)	1996-09-13	2003-01-28	New Life Pharmaceuticals Inc.	Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6028064A (en)	1996-09-13	2000-02-22	New Life Pharmaceuticals Inc.	Prevention of ovarian cancer by administration of progestin products
US6765002B2 (en)	2000-03-21	2004-07-20	Gustavo Rodriguez	Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6034074A (en)	1996-09-13	2000-03-07	New Life Pharmaceuticals Inc.	Prevention of ovarian cancer by administration of a Vitamin D compound
AU5873300A (en) *	1999-07-07	2001-01-30	Pharmacia & Upjohn Company	Process to prepare exemestane
GB9930839D0 (en) *	1999-12-30	2000-02-16	Pharmacia & Upjohn Spa	Process for treating gynecomastia
GB0005257D0 (en) *	2000-03-03	2000-04-26	Pharmacia & Upjohn Spa	Breast cancer hormonal therapy
US20010044431A1 (en) *	2000-03-21	2001-11-22	Rodriguez Gustavo C.	Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
GB0017635D0 (en) *	2000-07-18	2000-09-06	Pharmacia & Upjohn Spa	Antitumor combined therapy
US20030158168A1 (en) *	2000-08-09	2003-08-21	Giorgio Massimini	Composition for combined use of aromatase inhibitors
MXPA03001983A (es) *	2000-09-08	2003-06-24	Pharmacia Italia Spa	Exemestano como agente quimiopreventivo.
US20040082557A1 (en) *	2001-01-26	2004-04-29	Wajszczuk Charles Paul	Methods for treating estrogen-dependent disorders
WO2002072106A2 (en) *	2001-01-26	2002-09-19	Pharmacia Italia Spa	Combined method for treating hormono-dependent disorders with exemestane
CA2994779C (en)	2001-02-19	2020-08-25	Novartis Ag	Use of 40-o-(2-hydroxyethyl)-rapamycin for inhibiting growth of a solid tumour of the brain other than lymphatic cancer
PT1392313E (pt)	2001-05-16	2007-07-17	Novartis Ag	Combinação que compreende n - ( 5- [ 4- ( metil-piperazinomrtil ) - benxoilamido ] - 2 -metilfenil ) - 4 -( 3 - piridil ) - 2 - pirimidina-amina e um agente quimioterapêutico
GB0120147D0 (en) *	2001-08-17	2001-10-10	Metris Therapeutics Ltd	Treatment method
US20040043938A1 (en) *	2001-11-06	2004-03-04	Dinesh Purandare	Combination therapy for estrogen-dependent disorders
GB0128510D0 (en) *	2001-11-28	2002-01-23	Novartis Ag	Organic compounds
BR0311173A (pt)	2002-05-16	2005-03-15	Novartis Ag	Uso de agentes de ligação do receptor de edg em câncer
CN1317293C (zh) *	2002-10-24	2007-05-23	南京长澳医药科技有限公司	一种依西美坦的合成工艺
CN1304413C (zh) *	2002-10-24	2007-03-14	上海华拓医药科技发展有限公司	一种抗癌药物依西美坦制备方法
US20040186160A1 (en) *	2002-12-13	2004-09-23	Sugen, Inc.	Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
WO2005027916A1 (en) *	2003-09-19	2005-03-31	Pfizer Products Inc.	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and aromatase inhibitors
US20050101579A1 (en) *	2003-11-06	2005-05-12	Shippen Eugene R.	Endometriosis treatment protocol
ES2382609T3 (es)	2004-01-16	2012-06-11	Cedarburg Pharmaceuticals, Inc.	Exemestano y sus productos intermedios y métodos de preparación de los mismos
US7435757B2 (en) *	2004-07-02	2008-10-14	Schering Ag	2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
EP1931385B1 (en)	2005-09-30	2018-02-28	Endece, LLC	(s)-6-methyloxaalkyl exemestane compounds and related methods of use
US10174070B2 (en)	2005-09-30	2019-01-08	Endece Llc	6-substituted estradiol derivatives and methods of use
US8168621B2 (en)	2005-09-30	2012-05-01	Endece, Llc	6-substituted estradiol derivatives and methods of use
US20080119447A1 (en) *	2005-09-30	2008-05-22	James Yarger	6-alkoxyalkyl estradiol derivatives and methods of use
DE102006008074B4 (de) *	2006-02-22	2013-08-14	RUHR-UNIVERSITäT BOCHUM	Behandlung von Krebs mit Geruchsrezeptor-Liganden
CA2649792A1 (en)	2006-05-09	2007-11-15	Novartis Ag	Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
US20080161324A1 (en) *	2006-09-14	2008-07-03	Johansen Lisa M	Compositions and methods for treatment of viral diseases
US20080275259A1 (en) *	2007-05-04	2008-11-06	Scinopharm Taiwan, Ltd	Process for preparing aromatase inhibitors
US8372887B2 (en)	2007-10-16	2013-02-12	Repros Therapeutics Inc.	Trans-clomiphene for metabolic syndrome
EP2070943A1 (en) *	2007-12-14	2009-06-17	Crystal Pharma, S.A.	Process for obtaining 6-Alkylidenandrost-1,4-diene-3one
CN101468023B (zh) *	2007-12-26	2011-02-02	上海复星医药（集团）股份有限公司	依西美坦片及其制备工艺
WO2009093262A2 (en) *	2008-01-21	2009-07-30	Cadila Healthcare Limited	Process for preparing aromatase inhibitor exemestane
GB0813628D0 (en) *	2008-07-25	2008-09-03	Arrow Int Ltd	Stable coated anti-cancer agent
WO2010076811A2 (en) *	2008-12-30	2010-07-08	Ind-Swift Laboratories Limited	Process for the preparation of exemestane
US8377454B2 (en)	2009-05-01	2013-02-19	Parviz Gharagozloo	Treating male infertility secondary to sperm oxidative stress
DE102010003494A1 (de) *	2010-03-31	2011-10-06	Bayer Schering Pharma Aktiengesellschaft	Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
EP2556082B1 (en)	2010-04-08	2017-02-22	Emory University	Substituted androst-4-ene diones
WO2011128434A2 (en)	2010-04-16	2011-10-20	Novartis Ag	Treatment of endocrine resistant breast cancer
US20120071455A1 (en)	2010-09-14	2012-03-22	Yarger James G	6-substituted demethyl-estradiol derivatives as selective er-beta agonists
CN104244953A (zh)	2012-02-29	2014-12-24	利普生物药剂公司	用于治疗雄激素缺乏的联合治疗
KR20160110963A (ko)	2014-02-11	2016-09-23	노파르티스 아게	암 치료를 위한 pi3k 억제제를 포함하는 제약 조합물
EP3373967B9 (en)	2015-11-10	2023-10-04	Paracrine Therapeutics AB	Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen
CN112409432B (zh) *	2020-11-16	2023-07-07	陕西理工大学	一种依西美坦的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB929985A (it) *
US2744120A (en) *	1953-01-14	1956-05-01	Olin Mathieson	1-dehydrotestololactone
US3112305A (en) *	1960-11-07	1963-11-26	British Drug Houses Ltd	6-methylene-3-oxo-delta4-steroids and process for their preparation
GB1042291A (en) *	1961-11-08	1966-09-14	Organon Labor Ltd	í¸-6ª‡-amino steroids and the preparation thereof
DK120154B (da) *	1968-02-29	1971-04-19	Schering Ag	Fremgangsmåde til fremstilling af N-substituerede 4-amino-3-oxosteroid-4,6-diener af androstan- eller pregnanrækken eller deres ammoniumsalte.
BE759143A (fr) *	1969-11-19	1971-05-19	Upjohn Co	Procede de preparation d'un nouveau compose steroide
US4235893A (en) *	1978-05-08	1980-11-25	Brodie Angela M	Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis
DE3004508C2 (de) *	1980-02-05	1981-12-10	Schering Ag Berlin Und Bergkamen, 1000 Berlin	Verfahren zur Herstellung von 6-Methylensteroiden
DE3322285A1 (de) *	1983-06-18	1984-12-20	Schering AG, 1000 Berlin und 4709 Bergkamen	1-alkyl-androsta-1,4-dien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US4512986A (en) *	1983-07-26	1985-04-23	Research Triangle Institute	Progrestationally active steroids
GB8517360D0 (en) *	1985-07-09	1985-08-14	Erba Farmitalia	Substituted androsta-1,4-diene-3,17-diones

1985
- 1985-07-09 GB GB858517360A patent/GB8517360D0/en active Pending
1986
- 1986-06-24 ES ES556550A patent/ES8801304A1/es not_active Expired
- 1986-07-02 IT IT21004/86A patent/IT1196436B/it active Protection Beyond IP Right Term
- 1986-07-04 CH CH2706/86A patent/CH668599A5/de not_active IP Right Cessation
- 1986-07-04 IL IL79336A patent/IL79336A/xx not_active IP Right Cessation
- 1986-07-04 HU HU862820A patent/HU194274B/hu unknown
- 1986-07-04 AT AT0181986A patent/AT395157B/de not_active IP Right Cessation
- 1986-07-07 AU AU59799/86A patent/AU578840B2/en not_active Expired
- 1986-07-07 US US06/882,364 patent/US4808616A/en not_active Expired - Lifetime
- 1986-07-07 FI FI862871A patent/FI83424C/fi not_active IP Right Cessation
- 1986-07-07 NZ NZ216763A patent/NZ216763A/en unknown
- 1986-07-07 IE IE182186A patent/IE58949B1/en not_active IP Right Cessation
- 1986-07-08 SU SU864027793A patent/SU1442077A3/ru active
- 1986-07-08 KR KR1019860005489A patent/KR950003614B1/ko not_active IP Right Cessation
- 1986-07-08 YU YU1201/86A patent/YU44585B/xx unknown
- 1986-07-08 SE SE8603046A patent/SE468988B/sv not_active IP Right Cessation
- 1986-07-08 ZA ZA865079A patent/ZA865079B/xx unknown
- 1986-07-08 BE BE0/216890A patent/BE905067A/fr not_active IP Right Cessation
- 1986-07-08 NO NO862753A patent/NO165547C/no not_active IP Right Cessation
- 1986-07-08 FR FR8609922A patent/FR2584725B1/fr not_active Expired
- 1986-07-08 JP JP61158891A patent/JPS6212797A/ja active Granted
- 1986-07-08 PH PH33989A patent/PH21785A/en unknown
- 1986-07-08 DK DK324386A patent/DK163520C/da not_active IP Right Cessation
- 1986-07-08 GR GR861780A patent/GR861780B/el unknown
- 1986-07-08 CA CA000513267A patent/CA1277656C/en not_active Expired - Lifetime
- 1986-07-08 CN CN86104664A patent/CN86104664B/zh not_active Expired
- 1986-07-08 NL NL8601785A patent/NL193616C/nl not_active IP Right Cessation
- 1986-07-08 GB GB08616585A patent/GB2177700B/en not_active Expired
- 1986-07-08 PT PT82944A patent/PT82944B/pt unknown
- 1986-07-08 DE DE2001199030 patent/DE10199030I1/de active Pending
- 1986-07-08 UA UA4027793A patent/UA6046A1/uk unknown
- 1986-07-09 CS CS873216A patent/CS258498B2/cs not_active IP Right Cessation
- 1986-07-09 CS CS865214A patent/CS257794B2/cs not_active IP Right Cessation
1987
- 1987-03-26 ES ES557466A patent/ES8802429A1/es not_active Expired
- 1987-06-05 YU YU1036/87A patent/YU44628B/xx unknown
- 1987-10-15 SU SU874203488A patent/SU1501923A3/ru active
1988
- 1988-07-26 US US07/225,674 patent/US4904650A/en not_active Expired - Lifetime
- 1988-12-30 MY MYPI88001585A patent/MY102294A/en unknown
1990
- 1990-10-03 SG SG804/90A patent/SG80490G/en unknown
- 1990-11-15 HK HK941/90A patent/HK94190A/xx not_active IP Right Cessation
1991
- 1991-12-30 SK SK4135-91A patent/SK413591A3/sk unknown
- 1991-12-30 CZ CS914135A patent/CZ413591A3/cs unknown
1994
- 1994-02-22 BG BG098516A patent/BG61370B2/bg unknown
1997
- 1997-04-08 BR BR1100240-9A patent/BR1100240A/pt active IP Right Grant
2000
- 2000-09-14 NL NL300017C patent/NL300017I2/nl unknown
- 2000-10-05 NO NO2000009C patent/NO2000009I1/no unknown

Also Published As

Publication number	Publication date
DK163520B (da)	1992-03-09
FR2584725A1 (fr)	1987-01-16
CN86104664A (zh)	1987-02-18
MY102294A (en)	1992-05-15
DK324386A (da)	1987-01-10
JPH0443919B2 (it)	1992-07-20
ATA181986A (de)	1992-02-15
SG80490G (en)	1990-11-23
IL79336A0 (en)	1986-10-31
AT395157B (de)	1992-10-12
SK413591A3 (en)	1995-07-11
GB8616585D0 (en)	1986-08-13
ZA865079B (en)	1987-03-25
KR950003614B1 (ko)	1995-04-17
FI83424B (fi)	1991-03-28
US4808616A (en)	1989-02-28
JPS6212797A (ja)	1987-01-21
NL193616B (nl)	1999-12-01
NL8601785A (nl)	1987-02-02
FI862871A (fi)	1987-01-10
KR870001140A (ko)	1987-03-11
DK324386D0 (da)	1986-07-08
CH668599A5 (de)	1989-01-13
CS257794B2 (en)	1988-06-15
FI83424C (fi)	1991-07-10
YU103687A (en)	1988-08-31
ES8801304A1 (es)	1987-12-16
NO2000009I1 (no)	2000-10-05
GB2177700B (en)	1988-12-07
IT8621004A0 (it)	1986-07-02
GB2177700A (en)	1987-01-28
SU1501923A3 (ru)	1989-08-15
YU44628B (en)	1990-10-31
CZ413591A3 (en)	1994-03-16
SE468988B (sv)	1993-04-26
CS521486A2 (en)	1987-09-17
HU194274B (en)	1988-01-28
PH21785A (en)	1988-02-24
IT1196436B (it)	1988-11-16
FI862871A0 (fi)	1986-07-07
SE8603046L (sv)	1987-01-10
NZ216763A (en)	1988-05-30
SE8603046D0 (sv)	1986-07-08
ES556550A0 (es)	1987-12-16
US4904650A (en)	1990-02-27
NO862753D0 (no)	1986-07-08
YU44585B (en)	1990-10-31
AU5979986A (en)	1987-01-15
ES557466A0 (es)	1988-06-01
FR2584725B1 (fr)	1988-05-13
NL193616C (nl)	2000-04-04
PT82944A (en)	1986-08-01
CS258498B2 (en)	1988-08-16
GR861780B (en)	1986-11-11
NL300017I1 (nl)	2000-11-01
NL300017I2 (nl)	2001-01-02
CN86104664B (zh)	1988-06-29
HUT42780A (en)	1987-08-28
NO165547B (no)	1990-11-19
UA6046A1 (uk)	1994-12-29
DK163520C (da)	1992-07-27
PT82944B (pt)	1989-01-30
CA1277656C (en)	1990-12-11
HK94190A (en)	1990-11-23
BE905067A (fr)	1987-01-08
AU578840B2 (en)	1988-11-03
IL79336A (en)	1991-06-10
NO862753L (no)	1987-01-12
GB8517360D0 (en)	1985-08-14
NO165547C (no)	1991-02-27
DE10199030I1 (de)	2001-10-04
IE58949B1 (en)	1993-12-01
ES8802429A1 (es)	1988-06-01
YU120186A (en)	1988-02-29
SU1442077A3 (ru)	1988-11-30
BR1100240A (pt)	1999-12-28
IE861821L (en)	1987-01-09

Publication	Publication Date	Title
BG61370B2 (bg)	1997-06-30	Заместени андроста-1,4-диен-3,17-диони и метод за тяхното получаване
EP0260975B1 (en)	1989-07-19	4-substituted 6- alkylidenandrostene-3,17-dione derivatives and process for their preparation
JP2643943B2 (ja)	1997-08-25	新規な６−もしくは７−メチレンアンドロスタ−１，４−ジエン−３，１７−ジオン誘導体およびその製造方法
JP2677626B2 (ja)	1997-11-17	１７−置換アンドロスタ−１，４−ジエン−３−オン誘導体
US4840943A (en)	1989-06-20	Androst-4-ene-3,17-diones and process for their preparation
JPH04117394A (ja)	1992-04-17	１０位置に置換エチル基を含有する新規のステロイド化合物、それらの製造方法、それらの薬剤としての使用及びそれらを含有する製薬組成物
US4771043A (en)	1988-09-13	Steroidic aromatase inhibitors
US4810423A (en)	1989-03-07	1,2-beta-methylene-4-substituted androstene-3,17-dione derivatives and process for their preparation
US5457097A (en)	1995-10-10	Androst-4-eno[4,5-b]pyrrole derivatives
DE3622841C2 (de)	2001-01-25	Substituierte Androsta-1,4-dien-3,17-dione und Verfahren zu deren Herstellung
HU199157B (en)	1990-01-29	Process for producing 17-substituted androsta-1,4-dien-3-one derivatives and pharmaceutical compositions comprising same as active ingredient